ENDRA Life Sciences to Participate in Two Upcoming Investment Conferences

Rhea-AI Summary

ENDRA Life Sciences Inc. (NASDAQ:NDRA) will participate in two upcoming virtual investment conferences. The H.C. Wainwright Global Life Sciences Virtual Conference is scheduled for March 9-10, 2021, where management will give a presentation and hold one-on-one meetings. A recorded presentation will be available on demand from March 9, 2021. The 33rd Annual ROTH Conference will take place from March 15-19, 2021, with similar opportunities. ENDRA develops the Thermo Acoustic Enhanced UltraSound (TAEUS^®) technology, aiming to improve liver health diagnostics.

ANN ARBOR, MI / ACCESSWIRE / March 2, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), announces that management will participate in two upcoming virtual investment conferences.

• H.C. Wainwright Global Life Sciences Virtual Conference, March 9-10, 2021. Management will deliver a company presentation and will be available for one-on-one meetings. A webcast of the recorded presentation will be accessible on demand beginning Tuesday, March 9, 2021 for registered participants of the conference.

• 33^rd Annual ROTH Conference, March 15-19, 2021. Management will deliver a company presentation and will be available for one-on-one meetings. A webcast of the recorded presentation will be available on demand in the Investors section of ENDRA Life Sciences' website starting March 8, 2021.

About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50^th the cost and at the point of patient care. TAEUS^® is designed to work in concert with the over 1 million ultrasound systems in use globally today. TAEUS^® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS^®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.

Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com

Investor Relations Contact:
Kim Sutton Golodetz
LHA Investor Relations
(212) 838-3777
kgolodetz@lhai.com

SOURCE: ENDRA Life Sciences Inc.

View source version on accesswire.com:
https://www.accesswire.com/632459/ENDRA-Life-Sciences-to-Participate-in-Two-Upcoming-Investment-Conferences

FAQ

What conferences will ENDRA Life Sciences participate in March 2021?

ENDRA Life Sciences will participate in the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021, and the 33rd Annual ROTH Conference from March 15-19, 2021.

When will ENDRA Life Sciences' presentations be available to view?

ENDRA Life Sciences' presentation from the H.C. Wainwright conference will be available on demand starting March 9, 2021. The presentation from the ROTH Conference will be available on March 8, 2021.

What is the focus of ENDRA Life Sciences' TAEUS technology?

The TAEUS technology from ENDRA aims to visualize tissue similar to MRI but at a significantly lower cost, focusing primarily on measuring fat in the liver and assessing Non-Alcoholic Fatty Liver Disease (NAFLD).

How does TAEUS technology assist in diagnosing liver conditions?

TAEUS technology is designed to help visualize tissue conditions such as NAFLD and NASH, addressing the diagnostic challenges associated with these chronic liver diseases.

What is the significance of the investment conferences for ENDRA Life Sciences?

The investment conferences provide ENDRA Life Sciences an opportunity to present their advancements in TAEUS technology and connect with potential investors.